Skip to main content
SpringerLink
Log in

Antiangiogenesis: New frontiers in therapeutic development

  • Meeting report
  • Published:
Angiogenesis Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Marler JJ, Fishman SJ, Kilroy SM et al (2005) Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics 116: 38–45

    Article  PubMed  Google Scholar 

  2. Dowlati A, Robertson K, Radivoyevitch T et al (2005) Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res 11: 7938–44

    Article  PubMed  CAS  Google Scholar 

  3. Hida K, and Klagsbrun M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65: 2507–10

    Article  PubMed  CAS  Google Scholar 

  4. Peng SB, Yan L, Xia X et al (2005) Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry 22: 2293–304

    Article  Google Scholar 

  5. LaMontagne K, Littlewood-Evans A, Schnell C et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res (In press)

  6. Glade Bender J, Cooney EM, Kandel JJ, and Yamashiro DJ (2004) Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 7: 289–300

    Article  PubMed  CAS  Google Scholar 

  7. Peters BA, Diaz LA, Polyak K et al (2005) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 11: 261–2

    Article  PubMed  CAS  Google Scholar 

  8. Carano RA, Ross AL, Ross J et al (2004) Quantification of tumor tissue populations by multispectral analysis. Magn Reon Med 51: 542–51

    Article  Google Scholar 

  9. Drevs J, Konerding MA, Wolloscheck T et al (2004) The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 7: 347–54

    Article  PubMed  CAS  Google Scholar 

  10. Shukeir N, Garde S, Wu JJ et al. (2005) Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs 16: 1045–51

    Article  PubMed  CAS  Google Scholar 

  11. Khanna C and Hunter K (2005) Modeling metastasis in vivo. Carcinogenesis 26: 513–23

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Therapeutics, Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersy, USA

    Kenneth R. LaMontagne

  2. Cancer Therapeutics, Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ, USA

    Kenneth R. LaMontagne

Authors
  1. Kenneth R. LaMontagne
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth R. LaMontagne.

Rights and permissions

Reprints and permissions

About this article

Cite this article

LaMontagne, K.R. Antiangiogenesis: New frontiers in therapeutic development. Angiogenesis 8, 285–287 (2006). https://doi.org/10.1007/s10456-005-9025-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10456-005-9025-6

Keywords

Search

Navigation